Skip to content

LD-Oncologic

Active Private limited companyfounded 2013active for 13 yearsRue des Ecoles 7, 5520 OnhayeKBO/BCE: BE 0533.702.512

Lifetime

13 annual accounts with figures on one time axis
peak of €69,307 in 2025
€69,307▲ 11.0%
lowest -€90,470 in 2014
€39,623▲ 14.0%
peak of €140,314 in 2025
€140,314▲ 23.7%
€128,136▼ 2.0%
Board2 names since 2013
2 directors and 1 other
Documentsfilings and deeds
15-07-202616 days before the deadline
2025micro format
Equity from €113,459 to €140,314Investments €17,314Cash from €15,893 to €39,475

Key points

from the 2025 annual accounts

Equity

€140,314 ▲ 23.7%

LD-Oncologic has made a profit without a break since 2015.

Investments

€17,314 3.1 times depreciation
202220242025

Green is investment, beige is depreciation.

Filings

13 annual accounts since 2013
AprilJune31 JulyOctober201520202025

Five of the last ten came late. The 2023 accounts came in latest, 30 days after the end of the period.

Checked score

Bankruptcy probability within 12 months

Financial strength

Score breakdown

Comparable companies, two years later

In July 2024, 34,724 companies had the same profile as LD-Oncologic has now. Each dot stands for 87 companies, two years later.

95.3%
were still trading
4.0%
stopped another way
0.7%
went bankrupt
  • Micro
  • 10 to 20 years old
  • solvency 30% or more
  • a profit of 5% of the balance sheet or more
Test of the method

The method was tested on the 497,894 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.7% would go bankrupt within 24 months. In fact 1.8% went bankrupt.

The companies in ten equal groups, from the lowest to the highest expected share
Group Expected Actual
1 0.2% 0.2%
2 0.4% 0.5%
3 0.6% 0.6%
4 0.7% 0.8%
5 0.9% 1.0%
6 1.4% 1.6%
7 1.7% 1.8%
8 1.9% 2.0%
9 3.1% 3.3%
10 5.9% 6.4%

A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.

This is an observation about 34,724 companies, not a prediction for LD-Oncologic. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.

Credit verdict

Credit check for an amount and term of your choice

Show the recommended maximum and see how the verdict changes with amount, term and advance.

The scores and ratios are Checked's own calculations, not a credit decision.

Signals

Board and ownership

Director
Director
  • mandate holderdeed of 11-07-2013
Board & ownership

Recent changes

Registered in the Peppol Directory Reachable for e-invoices through 0208:0533702512
Company renamed from Docteur to LD-Oncologic (director) and (director) change roles · “article 4 des statuts ci-dessous” (deed in French) · Discharge granted to · Gazette deed
is in office as manager Partner: (mandate holder) · Gazette deed
Incorporation Founding capital of €18,600, 100 shares, €12,400 paid up · Founded by (constituant) · (manager) and (manager) appointed · published on 30-04-2013 · Gazette deed
All 22 events

Official details

Source: KBO
Status
Active since 26-04-2013Normal situation
Activity
Specialist medical practiceNACE 862201 activity on the establishment unitFrom the articles, 6 activities
Establishment unit
2.220.816.6815520 Onhaye, since 26-04-2013
Financial year end
31 December
Peppol
Reachable since 24-08-2026
Company details

Annual accounts 2025

≈ €210,000estimated
€268,450▲ 9.9%
Filing
Filed on 15-07-2026, 16 days before the end of the filing period
Financials

Insights on LD-Oncologic

LD-Oncologic files the micro format. That format states no turnover. The gross margin rose from €50,580 in 2013 to €69,307 in 2025.

The balance sheet grew most from 2024 to 2025 through fixed assets.

Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.

Key facts about LD-Oncologic

What is the company number of LD-Oncologic?
The company number of LD-Oncologic is 0533.702.512. The VAT number is the same number with BE in front: BE 0533.702.512.
Where is LD-Oncologic based?
The registered office is at Rue des Ecoles 7, 5520 Onhaye.Company details
What does LD-Oncologic do?
According to the KBO register, the main activity of the establishment unit is specialist medical practice (NACE 86220).
What is the legal form of LD-Oncologic?
LD-Oncologic is a private limited company (BV).
When was LD-Oncologic founded?
LD-Oncologic was founded on 26-04-2013.
Is LD-Oncologic still active?
Yes, LD-Oncologic is an active enterprise in the KBO register.
What is the turnover of LD-Oncologic?
The turnover in financial year 2025 is about €210,000. This figure is estimated from the gross margin of €69,307 and 2,989 comparable companies of the same size. It probably lies between €140,000 and €360,000. It is a rough estimate. In financial year 2023 turnover was €181,408.Financials
Is LD-Oncologic profitable?
In financial year 2025, LD-Oncologic made a profit of €39,623.
Where can I find the annual accounts of LD-Oncologic?
LD-Oncologic filed 13 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
When are the next annual accounts of LD-Oncologic due?
LD-Oncologic must file the annual accounts for financial year 2026 by 31-07-2027.Timeline

Next steps

See how customers, suppliers and banks see your own company and what to improve first.

Keep this company with today's facts in a case file.